RhumbLine Advisers’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.43M | Buy |
125,227
+14,739
| +13% | +$168K | ﹤0.01% | 2067 |
|
|
2025
Q1 | $1.31M | Buy |
110,488
+7,255
| +7% | +$86.2K | ﹤0.01% | 2042 |
|
|
2024
Q4 | $1.94M | Buy |
103,233
+12,315
| +14% | +$232K | ﹤0.01% | 1892 |
|
|
2024
Q3 | $2.04M | Buy |
90,918
+2,137
| +2% | +$48K | ﹤0.01% | 1901 |
|
|
2024
Q2 | $1.85M | Buy |
88,781
+11,010
| +14% | +$230K | ﹤0.01% | 1924 |
|
|
2024
Q1 | $1.14M | Buy |
77,771
+2,664
| +4% | +$39.2K | ﹤0.01% | 2181 |
|
|
2023
Q4 | $775K | Buy |
75,107
+58
| +0.1% | +$599 | ﹤0.01% | 2403 |
|
|
2023
Q3 | $590K | Buy |
75,049
+1,993
| +3% | +$15.7K | ﹤0.01% | 2515 |
|
|
2023
Q2 | $730K | Buy |
73,056
+244
| +0.3% | +$2.44K | ﹤0.01% | 2463 |
|
|
2023
Q1 | $647K | Buy |
72,812
+2,045
| +3% | +$18.2K | ﹤0.01% | 2317 |
|
|
2022
Q4 | $777K | Buy |
70,767
+677
| +1% | +$7.43K | ﹤0.01% | 2262 |
|
|
2022
Q3 | $913K | Buy |
70,090
+7,051
| +11% | +$91.8K | ﹤0.01% | 2177 |
|
|
2022
Q2 | $799K | Buy |
63,039
+29,528
| +88% | +$374K | ﹤0.01% | 2248 |
|
|
2022
Q1 | $469K | Buy |
33,511
+1,573
| +5% | +$22K | ﹤0.01% | 2448 |
|
|
2021
Q4 | $925K | Buy |
31,938
+864
| +3% | +$25K | ﹤0.01% | 2244 |
|
|
2021
Q3 | $931K | Buy |
31,074
+1,258
| +4% | +$37.7K | ﹤0.01% | 2251 |
|
|
2021
Q2 | $791K | Buy |
29,816
+5,601
| +23% | +$149K | ﹤0.01% | 2347 |
|
|
2021
Q1 | $753K | Buy |
24,215
+12,592
| +108% | +$392K | ﹤0.01% | 2312 |
|
|
2020
Q4 | $382K | Buy |
11,623
+2,110
| +22% | +$69.3K | ﹤0.01% | 2557 |
|
|
2020
Q3 | $332K | Buy |
+9,513
| New | +$332K | ﹤0.01% | 2467 |
|